GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.
GLP-1/glucagon dual receptor agonists may enhance MASH resolution and reduce liver fat, but further research is needed to confirm these findings and assess long-term effects.
Where it sits
this study against the rest of the survodutide (bi 456906) corpusSummary and findings
This systematic review and meta-analysis evaluated GLP-1/glucagon dual receptor agonists in adults with metabolic dysfunction-associated steatohepatitis (MASH). Four trials involving 673 participants were analyzed, revealing significant effects on MASH resolution and liver fat reduction. Adverse events such as nausea and vomiting were reported more frequently.
Abstract
<h4>Background</h4>Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with high unmet therapeutic need. GLP-1/glucagon dual receptor agonists are an emerging drug class, but no meta-analysis has evaluated it exclusively.<h4>Methods</h4>In this registered systematic review and meta-analysis (PROSPERO CRD420261325731), we searched PubMed, Embase, Cochrane, and Google Scholar through January 2026 for placebo-controlled randomized trials of GLP-1/glucagon dual agonists in adults with MASH or MASLD. Four trials (survodutide, pemvidutide, cotadutide; n=673) were pooled with DerSimonian-Laird random-effects models; Hartung-Knapp-Sidik-Jonkman adjustment was a sensitivity analysis.<h4>Results</h4>Dual agonists increased MASH resolution without worsening of fibrosis (RR 2.98, 95% CI 2.09-4.24; k=2). A borderline, exploratory signal for fibrosis improvement was observed (RR 1.38, 95% CI 1.01-1.88; p=0.044; k=2); neither trial was individually significant. Relative liver fat fell by 46.24% (95% CI -55.24 to -37.24), and ≥30% liver fat reduction was more frequent (RR 4.39, 95% CI 2.97-6.49). ALT (MD -20.38 IU/L, 95% CI -33.00 to -7.75), AST (MD -18.80 IU/L), body weight (MD -4.36%) and systolic blood pressure (MD -5.22 mmHg) decreased; the ELF reduction was not retained in sensitivity analyses. Nausea (RR 2.90), vomiting (RR 9.58) and diarrhea (RR 1.90) were more frequent; serious adverse events were not (RR 1.06). Split-placebo analyses were consistent.<h4>Conclusions</h4>Dual agonists were associated with a higher likelihood of MASH resolution, a borderline exploratory fibrosis signal, and reductions in liver fat, liver enzymes, weight and systolic blood pressure, with more gastrointestinal adverse events. These early-phase findings support continued Phase 3 evaluation.
Background
This paper addresses the clinical question of whether GLP-1/glucagon dual receptor agonists can effectively treat metabolic dysfunction-associated steatohepatitis (MASH). Previous research has indicated a need for effective therapies for MASH, but no meta-analysis had specifically evaluated this drug class. The findings may provide insights into the potential benefits and risks of these dual agonists in managing MASH.
Methods
The study is a registered systematic review and meta-analysis that included placebo-controlled randomized trials of GLP-1/glucagon dual agonists in adults with MASH or MASLD. A total of four trials were pooled, involving 673 participants, using DerSimonian-Laird random-effects models for analysis. The primary outcome was MASH resolution, with secondary outcomes including liver fat reduction and liver enzyme levels.
Results
The primary endpoint showed an RR of 2.98 for MASH resolution without worsening of fibrosis (95% CI 2.09-4.24; k=2). Additionally, a borderline exploratory signal for fibrosis improvement was noted with an RR of 1.38 (95% CI 1.01-1.88; p=0.044; k=2). Relative liver fat decreased by 46.24% (95% CI -55.24 to -37.24), and there was an RR of 4.39 for achieving ≥30% liver fat reduction (95% CI 2.97-6.49).
Interpretation
The findings suggest that GLP-1/glucagon dual receptor agonists may improve MASH resolution and reduce liver fat, aligning with some prior literature on the efficacy of GLP-1 agonists. However, the effect sizes for some outcomes, particularly the exploratory fibrosis signal, may not be clinically meaningful given their borderline significance. Limitations such as small sample sizes and potential confounding factors related to adverse events should be considered when interpreting these results.
Key findings
- RR 2.98 for MASH resolution without worsening of fibrosis; 95% CI 2.09-4.24; k=2.
- RR 1.38 for exploratory fibrosis improvement; 95% CI 1.01-1.88; p=0.044; k=2.
- Relative liver fat fell by 46.24%; 95% CI -55.24 to -37.24.
- RR 4.39 for ≥30% liver fat reduction; 95% CI 2.97-6.49.
- MD -20.38 IU/L for ALT; 95% CI -33.00 to -7.75.
- MD -4.36% for body weight.
Limitations
- small n=673 across four trials
- borderline significance for exploratory fibrosis improvement
- potential confounding from gastrointestinal adverse events
- short follow-up duration not specified